A new cannabis chemovar index linked specific THC-terpene combinations to different patient outcomes

A novel indexing system classifying cannabis flower by cannabinoid and terpene combinations found that different chemovars were associated with distinct patient-reported outcomes for symptom relief and side effects.

Vigil, Jacob Miguel et al.·Journal of cannabis research·2023·lowObservational
RTHC-05002Observationallow2023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
low
Sample
N=204

What This Study Found

The Vigil Index of Cannabis Chemovars created a scalable classification system combining major cannabinoid and terpene contents. The most commonly consumed chemovars showed different effectiveness profiles and side effect patterns across 204 users.

Key Numbers

204 users from 2016-2021 tracked via mobile app. Cannabis flower classified by cannabinoid and terpene content into chemovars. Different chemovars associated with distinct treatment effectiveness and side effect profiles.

How They Did This

Observational study using a mobile app. 204 people tracked cannabis flower consumption between 2016-2021. Cannabis products were classified by cannabinoid and terpene profiles into chemovars. Patient-reported outcomes compared across chemovar categories.

Why This Research Matters

The cannabis market treats products as interchangeable within broad categories (indica, sativa, hybrid). A chemistry-based classification system could help patients and clinicians identify which specific formulations work for their needs.

The Bigger Picture

Moving from strain names to chemical profiles represents a fundamental shift in how cannabis products are understood. If specific cannabinoid-terpene combinations consistently produce different effects, it could transform cannabis from a black box into precision medicine.

What This Study Doesn't Tell Us

Small, self-selected sample of app users. Non-randomized, observational design. Cannabis product testing may not be perfectly accurate. Patient-reported outcomes are subjective. Chemovar categories may oversimplify complex plant chemistry.

Questions This Raises

  • ?Would larger validation studies confirm chemovar-outcome associations?
  • ?Could this indexing system be adopted by dispensaries to improve product selection guidance?

Trust & Context

Key Stat:
204 users tracked; different cannabinoid-terpene chemovars linked to distinct outcomes
Evidence Grade:
Novel observational framework with small sample. Proof-of-concept for a classification system that needs larger validation.
Study Age:
Published 2023. Data from 2016-2021.
Original Title:
Systematic combinations of major cannabinoid and terpene contents in Cannabis flower and patient outcomes: a proof-of-concept assessment of the Vigil Index of Cannabis Chemovars.
Published In:
Journal of cannabis research, 5(1), 4 (2023)
Database ID:
RTHC-05002

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Does the type of cannabis strain matter for medical effects?

This study suggests yes. When cannabis flower was classified by actual chemical content (cannabinoid and terpene levels) rather than just strain name, different chemical profiles were associated with different symptom relief and side effects. This supports the idea that specific chemical combinations matter.

What is a cannabis chemovar?

A chemovar (chemical variety) classifies cannabis by its actual phytochemical composition, especially cannabinoid and terpene levels. Unlike strain names, which are inconsistent across growers, chemovars reflect what is actually in the plant. The Vigil Index creates a systematic way to categorize and compare these chemical profiles.

Read More on RethinkTHC

Cite This Study

RTHC-05002·https://rethinkthc.com/research/RTHC-05002

APA

Vigil, Jacob Miguel; Stith, Sarah See; Brockelman, Franco; Keeling, Keenan; Hall, Branden. (2023). Systematic combinations of major cannabinoid and terpene contents in Cannabis flower and patient outcomes: a proof-of-concept assessment of the Vigil Index of Cannabis Chemovars.. Journal of cannabis research, 5(1), 4. https://doi.org/10.1186/s42238-022-00170-9

MLA

Vigil, Jacob Miguel, et al. "Systematic combinations of major cannabinoid and terpene contents in Cannabis flower and patient outcomes: a proof-of-concept assessment of the Vigil Index of Cannabis Chemovars.." Journal of cannabis research, 2023. https://doi.org/10.1186/s42238-022-00170-9

RethinkTHC

RethinkTHC Research Database. "Systematic combinations of major cannabinoid and terpene con..." RTHC-05002. Retrieved from https://rethinkthc.com/research/vigil-2023-systematic-combinations-of-major

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.